OBJECTIVE: Several components of the GH and IGF systems have been implicated in the development of malignancies. All components of these hormonal systems have never been jointly evaluated in female breast cancer, and previous studies have not examined the role of IGF-binding proteins (IGFBP-4, IGFBP-6) or GH-binding protein (GHBP). DESIGN: Hospital-based case-control study. METHODS: In this sample of primarily postmenopausal women, we obtained serum measures of IGF-I, IGF-II, and binding proteins IGFBP-1, IGFBP-3, IGFBP-4, IGFBP-6, as well as GHBP, insulin, and leptin from 74 breast cancer cases and 76 control subjects. RESULTS: In crude analyses, we found lower age-standardized mean IGF-I, IGFBP-3, IGFBP-4, IGFBP-6, and higher IGFBP-1 and GHBP in breast cancer cases when compared with controls. Multivariate models mutually adjusted for other GH-IGF system components and classical breast cancer risk factors demonstrated an inverse association between IGFBP-3 and risk of breast cancer (odds ratio (OR) = 0.2, P < 0.01) and a direct association between GHBP and disease risk (OR = 3.3, P < 0.01). No significant associations were detected in multivariate analyses among IGF-I, IGF-II or IGFBP-1, IGFBP-4, IGFBP-6 with risk of breast cancer, indicating that these factors may not have effects independent of and/or comparable with IGFBP-3 and GHBP. CONCLUSIONS: These results support a protective role of IGFBP-3 and demonstrate for the first time an increased risk of breast cancer with higher GHBP, after accounting for variation in IGFs, IGFBPs, and classical breast cancer risk factors.
OBJECTIVE: Several components of the GH and IGF systems have been implicated in the development of malignancies. All components of these hormonal systems have never been jointly evaluated in female breast cancer, and previous studies have not examined the role of IGF-binding proteins (IGFBP-4, IGFBP-6) or GH-binding protein (GHBP). DESIGN: Hospital-based case-control study. METHODS: In this sample of primarily postmenopausal women, we obtained serum measures of IGF-I, IGF-II, and binding proteins IGFBP-1, IGFBP-3, IGFBP-4, IGFBP-6, as well as GHBP, insulin, and leptin from 74 breast cancer cases and 76 control subjects. RESULTS: In crude analyses, we found lower age-standardized mean IGF-I, IGFBP-3, IGFBP-4, IGFBP-6, and higher IGFBP-1 and GHBP in breast cancer cases when compared with controls. Multivariate models mutually adjusted for other GH-IGF system components and classical breast cancer risk factors demonstrated an inverse association between IGFBP-3 and risk of breast cancer (odds ratio (OR) = 0.2, P < 0.01) and a direct association between GHBP and disease risk (OR = 3.3, P < 0.01). No significant associations were detected in multivariate analyses among IGF-I, IGF-II or IGFBP-1, IGFBP-4, IGFBP-6 with risk of breast cancer, indicating that these factors may not have effects independent of and/or comparable with IGFBP-3 and GHBP. CONCLUSIONS: These results support a protective role of IGFBP-3 and demonstrate for the first time an increased risk of breast cancer with higher GHBP, after accounting for variation in IGFs, IGFBPs, and classical breast cancer risk factors.
Authors: Brionna Y Hair; Melissa A Troester; Sharon N Edmiston; Eloise A Parrish; Whitney R Robinson; Michael C Wu; Andrew F Olshan; Theresa Swift-Scanlan; Kathleen Conway Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-01-12 Impact factor: 4.254
Authors: Virginia G Kaklamani; Thomas J Hoffmann; Timothy A Thornton; Geoffrey Hayes; Rowan Chlebowski; Linda Van Horn; Christos Mantzoros Journal: Breast Cancer Res Treat Date: 2013-04-30 Impact factor: 4.872
Authors: Virginia G Kaklamani; Maureen Sadim; Alex Hsi; Kenneth Offit; Carole Oddoux; Harry Ostrer; Habibul Ahsan; Boris Pasche; Christos Mantzoros Journal: Cancer Res Date: 2008-05-01 Impact factor: 12.701
Authors: Hong Jin Lee; Shiby Paul; Nadi Atalla; Paul E Thomas; Xinjie Lin; Ill Yang; Brian Buckley; Gang Lu; Xi Zheng; You-Rong Lou; Allan H Conney; Hubert Maehr; Luciano Adorini; Milan Uskokovic; Nanjoo Suh Journal: Cancer Prev Res (Phila) Date: 2008-11
Authors: Lauren Bassaro; Stephen J Russell; Elzbieta Pastwa; Stella A Somiari; Richard I Somiari Journal: Cancer Genomics Proteomics Date: 2017 Nov-Dec Impact factor: 4.069
Authors: Jo K Perry; Kumarasamypet M Mohankumar; B Starling Emerald; Hichem C Mertani; Peter E Lobie Journal: J Mammary Gland Biol Neoplasia Date: 2008-02-07 Impact factor: 2.673
Authors: Hui Pan; Lin-Li Deng; Jia-Qi Cui; Lin Shi; Yi-Chun Yang; Jiang-Hui Luo; Dan Qin; Li Wang Journal: Medicine (Baltimore) Date: 2018-07 Impact factor: 1.889